Literature DB >> 30219184

Radionuclide Therapy for Bone Metastases: Utility of Scintigraphy and PET Imaging for Treatment Planning.

Hojjat Ahmadzadehfar1, Markus Essler2, Kambiz Rahbar3, Ali Afshar-Oromieh4.   

Abstract

The skeleton is a common site for cancer metastases. Bone metastases are a major cause of morbidity and mortality and associated with pain, pathologic fractures, spinal cord compression, and decreased survival. Various radionuclides have been used for pain therapy. Recently, an α-emitter has been shown to improve overall survival of patients with bone metastases from castration-resistant prostate cancer and was approved as a therapeutic agent. The aim of this article is to provide an overview regarding state of the art radionuclide therapy options for bone metastases, with focus on the role of PET imaging in therapy planning.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bone metastases; Breast cancer; Lung cancer; PET; Prostate cancer; Radionuclide therapy; Radium-223

Mesh：

Substances：

Year:  2018        PMID： 30219184     DOI： 10.1016/j.cpet.2018.05.005

Source DB:  PubMed          Journal:  PET Clin        ISSN： 1556-8598


  5 in total

1.  The meta-analysis of the effect of 68Ga-PSMA-PET/CT diagnosis of prostatic cancer compared with bone scan.

Authors:  Ruining Zhao; Yajie Li; Lihong Nie; Kaiyue Qin; Hang Zhang; Hongbin Shi
Journal:  Medicine (Baltimore)       Date:  2021-04-16       Impact factor: 1.817

Review 2.  Radiotheranostics - Precision Medicine in Nuclear Medicine and Molecular Imaging.

Authors:  Heying Duan; Andrei Iagaru; Carina Mari Aparici
Journal:  Nanotheranostics       Date:  2022-01-01

3.  Application of machine learning to pretherapeutically estimate dosimetry in men with advanced prostate cancer treated with 177Lu-PSMA I&T therapy.

Authors:  Song Xue; Andrei Gafita; Chao Dong; Yu Zhao; Giles Tetteh; Bjoern H Menze; Sibylle Ziegler; Wolfgang Weber; Ali Afshar-Oromieh; Axel Rominger; Matthias Eiber; Kuangyu Shi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-06-30       Impact factor: 10.057

4.  Combined bone scintigraphy and fluorocholine PET/computed tomography predicts response to radium-223 therapy in patients with prostate cancer.

Authors:  Michele Klain; Valeria Gaudieri; Mario Petretta; Emilia Zampella; Giovanni Storto; Carmela Nappi; Carlo Buonerba; Felice Crocetto; Rosj Gallicchio; Fabio Volpe; Leonardo Pace; Martin Schlumberger; Alberto Cuocolo
Journal:  Future Sci OA       Date:  2021-05-21

5.  Assessing the quality of life of patients with metastatic castration-resistant prostate cancer with bone metastases receiving [223Ra]RaCl2 therapy.

Authors:  Miriam Sraieb; Nader Hirmas; Rupert Conrad; Milka Marinova; Markus Essler; Ken Herrmann; Hojjat Ahmadzadehfar
Journal:  Medicine (Baltimore)       Date:  2020-09-18       Impact factor: 1.817
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.